• Products
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Corporate/HUF Trading Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Trading Platforms
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Equity Screeners
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    SWP Calculator
    CAGR Calculator
    Simple Interest Calculator
    ELSS Calculator
    Step up SIP Calculator
    All Calculators
    Trading Platforms
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Share Market Today
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Stockshaala
    Basics of Stock Market
    Introduction to Fundamental Analysis
    Introduction to Technical Analysis
    Derivatives, Risk management & Option Trading Strategies
    Personal Finance
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Events
    Budget 2025
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2025
    Stockshaala
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

₹ 14938 / 22 shares

IPO Details

RHP/DRHP

Issue Date

30 Jul - 1 Aug'24

Investment/lot

₹ 14938

Price Range

646 - 679

Lot Size

22

IPO Size

₹ 1858.30 Cr

IPO Listing Details

Listing On

6 Aug'24

Issue Price

679

Listed Price

₹ 725

Retail Gain/Listing Gain

6.77%

Schedule of Akums Drugs and Pharmaceuticals IPO

Start date

30/07/2024

End date

01/08/2024

Allotment of bids

02/08/2024

Refund Initiation

05/08/2024

Listing on exchange

06/08/2024

Akum Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organisation (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

The company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections and gummies, among others.

With that, let's take a look at the competitive strengths and risk factors for Akum Drugs and Pharmaceuticals Limited:

Largest CDMO serving the Indian pharmaceutical industry

Akums Drugs and Pharmaceuticals Limited is the largest India-focused CDMO in terms of revenue, production capacity and clients served during the financial year 2023 (among CDMOs assessed by F&S) (Source: F&S Report). During the financial year 2024, the company had a market share of 30.2% by value in the Indian domestic CDMO market.

Diverse client base with longstanding CDMO relationships

As of March 31, 2024, their client base for their CDMO business comprised 1,524 Indian and multinational pharmaceutical and wellness companies, increasing from 1,386 as of March 31, 2022.

The market leader’s client base includes pharmaceutical companies, nutraceutical companies, cosmo-derma companies, wellness companies, e-commerce companies, healthcare providers and central and state government entities.

Large and rapidly growing R&D capabilities across their product portfolio:

As of March 31, 2024, the company operates four dedicated R&D units. They have also engaged 406 R&D scientists across their businesses. As of March 31, 2024, they have obtained 1,448 trademarks across various dosage forms and formulations.

Further, as of March 31, 2024, they have procured 927 DCGI approvals and 5 patents (Source: F&S Report). As of the date of this Red Herring Prospectus, they have received approval from FSSAI for 923 formulations.

  • They rely on domestic and international third-party suppliers for the supply of raw materials. Any delay, interruption or reduction in such supply could adversely affect their business, results of operations, etc.

  • The company had issued equity shares to more than 49 investors in the past, which may have been in non-compliance with the Companies Act, 1956.

  • The company has incurred losses in the past and may incur losses in the future.

Key Strategies

  • Leverage their leadership position to continue to increase their market share and consolidate their position in the CDMO market.

  • Sustain R&D for product development across therapies and dosage forms.

  • Expand their global presence through strategic initiatives.

Here are the key financials for Akums Drugs and Pharmaceuticals Limited:

Particulars (in Rs. million)

Particulars (in Rs. million)

Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO.

Here are the steps to apply for Akums Drugs & Pharmaceuticals Ltd IPO:

Step 1: Log in to your Kotak Securities Demat account Log in to your Demat account to access IPO investments. Next, select the current IPO section.

Step 2: Specify IPO details Enter the number of lots and the price you wish to apply for.

Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.

Step 4: Mandate Notification Your UPI app will receive a mandate notification to block funds.

Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.

Akums Drugs and Pharmaceuticals IPO FAQs

Akums Drugs and Pharmaceuticals IPO will list on 2024-08-06.

1858.30 is the issue size of Akums Drugs and Pharmaceuticals IPO.

The minimum lot size is 22 shares and the investment required is ₹14938.

The price band of Akums Drugs and Pharmaceuticals IPO is ₹646 to ₹679.

You can read more about Akums Drugs and Pharmaceuticals and its IPO from the company’s red herring prospectus (RHP) here.

The Akums Drugs and Pharmaceuticals Limited IPO has an issue size of Rs.1856.74 crores. The IPO opens for subscription on 30th July 2024 and closes on 1st Aug 2024

Link Intime India Private Limited is the registrar for this IPO.

Company NameBidding Dates
28 Apr - 30 Apr'25
29 Apr - 02 May'25
29 Apr - 06 May'25
Open Demat Account to Invest in any IPO
+91 -

personImage
Open Demat Account to Invest in any IPO
+91 -

N
N
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]